Naslov
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience

Autori
Tomasic, Vedran ; Drobne, David ; Borzan, Vladimir ; Bišćanin, Alen ; Hanžel, Jurij ; Oršić Frič, Vlasta ; Ćaćić, Petra, Štabuc, Borut ; Ogresta, Doris ; Kralj, Dominik ; Dorosulić, Zdravko ; Hrabar, Davor

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
UEG Week 2020 Poster Presentations / - : SAGE Publishing, 2020, 330-330

Skup
28th United European Gastroenterology Week (UEG 2020)

Mjesto i datum
Online, 11.10.2020. - 13.10.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
ustekinumab, Crohn disease

Sažetak
Introduction: Ustekinumab (UST) is a human anti- IL12/23 p40 monoclonal antibody, approved for treatment of Crohn’s Disease (CD). This multicenter, non-interventional, retrospective chart review explored robust real-life data in patients receiving UST to access long-term efficacy and treatment persistence of UST treatment in the bio- naive CD population with long-standing disease. Aims & Methods: Clinical data, such as maintenance of clinical response using Harvey-Bradshaw index, combined steroid-free and biochemical clinical remission, endoscopic response/healing via the simple endoscopic score for Crohn’s disease (SES-CD), dose escalation and treatment persistence were assessed in 42 adult patients (55% female ; mean age 46 ± 15.1 years ; mean BMI 25.28 ± 4.5 kg/m2 ) with long-standing (mean duration of 10, 5 years) biologic-naive CD from 3 tertiary centers (one Slovenian and two Croatian) between January 2018 and April 2020. Data were collected before first infusion, at week (W)24, W52, as well as last follow-up. Results: At W24 84% (35/42) of CD patients had achieved clinical response and 38.1% (16/42) were in combined steroid-free and biochemical clinical remission. After an average of 16 months of treatment duration, 88.1% (37/42) of CD patients were still on UST treatment, 71.4% (30/42) had maintained clinical response and 35.7% (15/42) were in sustained steroidfree clinical remission. The number of patients requiring steroid treatment was reduced by 87%. Mean HBI decreased from 8 to 3 and SES-CD from 6 to 2. The majority [59.53%] of patients started ustekinumab as monotherapy, i.e. without concomitant immunomodulator medication. 31% of patients experienced UST dose escalation. Conclusion: UST offers an effective and persistent steroid sparing treatment option in this real-life multicenter study of bio-naive CD patients with long-standing disease.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA